112 related articles for article (PubMed ID: 1295709)
21. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed to T cells or their subsets. II. Differential effectiveness of IgG2a and IgG2b isotypes of anti-CD3 and anti-CD4 moAb.
Knulst AC; Noort WA; Tibbe GJ; Benner R; Savelkoul HF
Bone Marrow Transplant; 1994 Oct; 14(4):535-43. PubMed ID: 7858528
[TBL] [Abstract][Full Text] [Related]
22. Antimurine antibody to OKT3 in cardiac transplantation: implications for prophylaxis and retreatment of rejection.
O'Connell JB; Bristow MR; Hammond EH; Menlove RL; Ensley RD; Ratkovec RM; Renlund DG
Transplant Proc; 1991 Feb; 23(1 Pt 2):1157-9. PubMed ID: 1899154
[No Abstract] [Full Text] [Related]
23. Devising murine models to better adapt clinical protocols: sequential low-dose treatment with anti-CD3 and anti-CD4 monoclonal antibodies to prevent fully mismatched allograft rejection.
Campos HH; Bach JF; Chatenoud L
Transplant Proc; 1993 Feb; 25(1 Pt 1):798-9. PubMed ID: 8438486
[No Abstract] [Full Text] [Related]
24. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies.
Woodle ES; Thistlethwaite JR; Jolliffe LK; Fucello AJ; Stuart FP; Bluestone JA
Transplantation; 1991 Aug; 52(2):361-8. PubMed ID: 1714644
[TBL] [Abstract][Full Text] [Related]
25. [T lymphocyte activation induced by monoclonal anti-CD3 antibodies: physiopathology of cytokine release].
Chatenoud L; Bach JF
C R Seances Soc Biol Fil; 1991; 185(5):268-77. PubMed ID: 1806186
[TBL] [Abstract][Full Text] [Related]
26. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
Waid TH; Lucas BA; Thompson JS; Munch LC; Brown S; Kryscio R; Prebeck R; VanHoy MA; Jezek D
Transplant Proc; 1991 Feb; 23(1 Pt 2):1062-5. PubMed ID: 1899152
[No Abstract] [Full Text] [Related]
27. Effect of HLA matching and T- and B-cell crossmatch on acute rejection and graft survival following liver transplantation.
Chen M; Wade J; Levy GA; Greig PD
Transplant Proc; 1994 Oct; 26(5):2695-6. PubMed ID: 7940844
[No Abstract] [Full Text] [Related]
28. Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: a comparative study.
Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
Hum Antibodies; 1997; 8(2):95-8. PubMed ID: 9289394
[TBL] [Abstract][Full Text] [Related]
29. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
Blazar BR; Taylor PA; Vallera DA
J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
[TBL] [Abstract][Full Text] [Related]
30. CD3-specific antibody-induced active tolerance: from bench to bedside.
Chatenoud L
Nat Rev Immunol; 2003 Feb; 3(2):123-32. PubMed ID: 12563296
[TBL] [Abstract][Full Text] [Related]
31. Humoral immune response against OKT3.
Chatenoud L
Transplant Proc; 1993 Apr; 25(2 Suppl 1):68-73. PubMed ID: 8465430
[No Abstract] [Full Text] [Related]
32. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
33. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic use of the OKT3 anti-T cell monoclonal antibody: mode of action and side effects.
Chatenoud L
Transplant Proc; 1988 Oct; 20(5 Suppl 6):79-83. PubMed ID: 3140452
[No Abstract] [Full Text] [Related]
35. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ
Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
[No Abstract] [Full Text] [Related]
36. Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells.
Abouna GM; Kumar MS; al-Abdullah IH; Loose J; Sullivan DK; Phillips K; Yost S; Seirka D
Transplant Proc; 1995 Oct; 27(5):2676-8. PubMed ID: 7482872
[No Abstract] [Full Text] [Related]
37. Structured to reduce the mitogenicity of anti-CD3 antibody based on computer-guided molecular design.
Lv M; Li Y; Yu M; Sun Y; Lin Z; Qiao C; Luo Q; Gu X; Huang Y; Feng J; Shen B
Int J Biochem Cell Biol; 2007; 39(6):1142-55. PubMed ID: 17446118
[TBL] [Abstract][Full Text] [Related]
38. Biological immunosuppressants: the way to clinical transplantation tolerance.
Chatenoud L
Transplant Proc; 1997; 29(1-2):51-5. PubMed ID: 9123108
[No Abstract] [Full Text] [Related]
39. Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions.
Alegre M; Depierreux M; Florquin S; Najdovski T; Vandenabeele P; Abramowicz D; Leo O; Deschodt-Lanckman M; Goldman M
Transplant Proc; 1990 Aug; 22(4):1920-1. PubMed ID: 2143864
[No Abstract] [Full Text] [Related]
40. Anti-CD3 and -CD4 monoclonal antibody in the treatment of steroid-resistant renal allograft rejection.
Wang XH; Xie T
Chin Med J (Engl); 1993 Nov; 106(11):821-4. PubMed ID: 8143493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
